Further studies on the anti-neoplastic activity of 3 beta-hydroxy-13 alpha-amino-13,17-seco-5 alpha-androstan-17-oic-13,17-lactam [p-[bis(2-chloroethyl)amino]-phenyl]acetate (NSC 290205).
The modified steroidal alkylating agent 3 beta-hydroxy-13 alpha-amino-13,17-seco-5 alpha-androstan-17-oic-13,17-lactam [p-[bis(2-chloroethyl)amino]phenyl]acetate (NSC 290205) is active in treating the LX-1 lung and MX-1 breast xenografts as well as a number of rodent tumors. Of 13 tumors tested, activity has been shown in 10 systems. Two systems have not received adequate testing and negative results were recorded in 1 system.
D000230:Adenocarcinoma / Q000188:drug therapy; D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001378:Azasteroids; D001943:Breast Neoplasms / Q000188:drug therapy; D002460:Cell Line; D003110:Colonic Neoplasms / Q000188:drug therapy; D004353:Drug Evaluation, Preclinical; D006801:Humans; D007942:Leukemia, Experimental / Q000188:drug therapy; D008175:Lung Neoplasms / Q000188:drug therapy; D008325:Mammary Neoplasms, Experimental / Q000188:drug therapy; D008545:Melanoma / Q000188:drug therapy; D051379:Mice; D009368:Neoplasm Transplantation; D009369:Neoplasms / Q000188:drug therapy*; D009588:Nitrogen Mustard Compounds / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D001378:Azasteroids; D009588:Nitrogen Mustard Compounds; C017888:NSC 290205